David A. Siegel Nurix Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 177,900 shares of NRIX stock, worth $3.71 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
177,900
Previous 29,100
511.34%
Holding current value
$3.71 Million
Previous $300,000
771.67%
% of portfolio
0.01%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NRIX
# of Institutions
144Shares Held
50.2MCall Options Held
30.3KPut Options Held
22.7K-
Black Rock Inc. New York, NY4.58MShares$95.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.48MShares$93.6 Million2.6% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$81 Million0.72% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$62.6 Million1.46% of portfolio
-
State Street Corp Boston, MA2.73MShares$57 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $984M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...